This is what analysts have to say about Cardiome Pharma Corp. (NASDAQ:CRME) after last week.

February 15, 2018 - By Marry Poplack

 This is what analysts have to say about Cardiome Pharma Corp. (NASDAQ:CRME) after last week.
Investors sentiment increased to 1.09 in Q3 2017. Its up 0.26, from 0.83 in 2017Q2. It is positive, as 2 investors sold Cardiome Pharma Corp. shares while 9 reduced holdings. 7 funds opened positions while 5 raised stakes. 13.54 million shares or 10.92% less from 15.20 million shares in 2017Q2 were reported.
Valley Natl Advisers accumulated 50 shares or 0% of the stock. Scotia invested in 0% or 19,120 shares. Royal Retail Bank Of Canada invested in 1,889 shares or 0% of the stock. Moreover, Jefferies Group Inc Inc Limited Liability Com has 0% invested in Cardiome Pharma Corp. (NASDAQ:CRME). New York-based Knott David M has invested 0.12% in Cardiome Pharma Corp. (NASDAQ:CRME). One Trading Ltd Partnership invested in 0% or 917 shares. Moreover, Art Advsr Limited Liability Company has 0% invested in Cardiome Pharma Corp. (NASDAQ:CRME) for 16,718 shares. Geode Capital Mngmt reported 18,731 shares or 0% of all its holdings. Clough Capital Ltd Partnership accumulated 2.88M shares. Morgan Stanley holds 0% or 2,100 shares. Wells Fargo & Mn, a California-based fund reported 800 shares. National Bank & Trust Of Montreal Can owns 1,004 shares. 1.20 million were reported by Rock Springs Mngmt Lp. Pnc Svcs Group Inc reported 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). Fincl Bank Of Nova Scotia holds 10 shares.

Cardiome Pharma Corp. (NASDAQ:CRME) Ratings Coverage

Among 6 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cardiome Pharma Corp had 15 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, August 22. The firm earned “Buy” rating on Wednesday, November 22 by H.C. Wainwright. The rating was initiated by H.C. Wainwright on Wednesday, June 1 with “Buy”. The rating was upgraded by Mackie to “Buy” on Friday, December 15. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) earned “Outperform” rating by Leerink Swann on Thursday, December 22. The stock has “Buy” rating by Zacks on Tuesday, August 11. On Wednesday, October 12 the stock rating was downgraded by Mackie to “Hold”. The company was reinitiated on Monday, July 17 by Canaccord Genuity. Brean Capital maintained it with “Buy” rating and $10 target in Friday, March 11 report. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) earned “Buy” rating by Canaccord Genuity on Wednesday, November 15. Below is a list of Cardiome Pharma Corp. (NASDAQ:CRME) latest ratings and price target changes.

15/12/2017 Broker: Mackie Rating: Buy Upgrade
22/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.5 Maintain
15/11/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $8 New Target: $5 Maintain
22/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.5 Maintain
21/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $8.0 Maintain

The stock increased 0.48% or $0.007 during the last trading session, reaching $1.467. About 13,876 shares traded. Cardiome Pharma Corp. (NASDAQ:CRME) has declined 11.02% since February 15, 2017 and is downtrending. It has underperformed by 27.72% the S&P500.

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. The company has market cap of $49.35 million. It offers BRINAVESS ) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It currently has negative earnings. The firm also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension.

More news for Cardiome Pharma Corp. (NASDAQ:CRME) were recently published by:, which released: “Cardiome Pharma: The Pieces Are Coming Together” on May 25, 2017.‘s article titled: “Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare …” and published on February 08, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.